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Bladder carcinoma is the fourth most common cancer in men and the eighth most common cancer among women. Our study is
aimed to characterise tumour-associated antigen peptides of transitional cell carcinoma of the bladder (TCC). A DNA micro-array-
based differential display analysis of 10000 genes was carried out, and MAGE-A8 gene expression was detected in the tumour, and
not in the normal bladder. High occurrence of MAGE-A8 expression was observed in fresh tumour samples (17 out of 23) and TCC
lines (four of eight). The MAGE-A8 protein sequence was screened for HLA-A2.1-binding motifs, six potential peptides were
synthesised, and peptides binding to HLA-A2.1 were assured. Immunogenicity and antigenicity of the MAGE-A8 peptides were
examined in the HHD system, murine class I MHC knockout mice, transgenic for HLA-A2.1. The MAGE-A8 peptide immunogenicity
was examined in three modes of vaccination, delivered intranasally with cholera toxin, injected into the tail base with complete
Freund’s adjuvant (CFA), or presented directly as loaded onto cell surface HLA-A2.1 molecules. Two peptides, 8.1 and 8.3, induce
CTL that kills the T24 TCC line in vitro, and prime human lymphocyte response of healthy donors. These results demonstrate the
potential use of the MAGE-A8 peptides for specific immunotherapy of TCC.
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Bladder cancer is the fifth common cancer in the USA, 95% of the
bladder cancers are defined as transitional cell carcinoma (TCC)
(Patton et al, 2002). There were 263000 cases of bladder cancer
diagnosed in the world, its incidence per 100000 people is 9.9 in
men and 2.3 in women.
Nonspecific immunotherapy with Bacillus Calmette-Guerin
(BCG), delivered intravesically, is the most active agent in the
treatment of superficial bladder cancer in reducing recurrence and
progression rate (Nseyo and Lamm, 1997). That may imply the
potential benefit of immunotherapeutic treatment for bladder
carcinoma.
Tumour-associated antigen (TAA) peptides are 8–10 amino
acids long, presented by class I MHC to cytotoxic, CD8
þ T cells of
the immune system (Renkvist et al, 2001). Among TAA groups are
the differentiation antigens, such as Tyrosinase, gp100 and
MART1/Melan-A in melanoma, and PSA in prostate carcinoma.
Tumour-associated antigens also originate from overexpressed
genes of the tumour, such as HER2/neu, CEA, or uniquely
expressed genes of the tumour, such as the MAGE gene
family. There are cases of viral proteins that serve as TAAs, such
as human papilloma virus 16 (HPV16)-E6, HPV-E7, and HTLV,
or Hepatitis B and C antigens, and mutated genes, as in the case
of b-catenin, CDK4, and CASP8. A case of fusion protein as a
source for TAA is of the bcr-abl of CML (reviewed in Renkvist et al,
2001).
The MAGE family was originally identified as genes that are
strictly expressed in tumour cells, but silent in normal adult
tissues, except in the male germ line and for some of the genes in
the placenta (Chomez et al, 2001). The first member of the MAGE
family was identified as a gene encoding for tumour-specific
antigen (van der Bruggen et al, 1991). A cluster of 12 MAGE genes
was later recognised, designated MAGE-A 1–12, it was mapped to
the q28 arm of the X chromosome (De Plaen et al, 1994). Two
more clusters were later identified, MAGE-B and MAGE-C, all the
genes in the three subfamilies are characterised by a long-terminal
exon, encoding the entire protein, and their expression is restricted
to tumours. Other subfamilies, MAGE-D, (Lucas et al, 1999) and
MAGE-E–L (Chomez et al, 2001) were also identified. Some of the
MAGE proteins take part in cell cycle regulation (Barker and
Salehi, 2002).
MAGE-A8 expression in normal tissues is limited to the testis
and the placenta (De Plaen et al, 1994). Its expression was
examined in 80 pairs of normal colon and colorectal carcinomas,
the MAGE-A8 gene was expressed in 44% of the tumour samples,
and not expressed in any of the 80 normal tissue (Hasegawa et al,
1998). An expression frequency of 46% was observed in 22 samples
of hepatocellular carcinoma (Tahara et al, 1999).
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examined in 57 samples of primary TCC, and varied from 21%
(MAGE-A1) to 35% (MAGE-A2), with higher expression level in
advanced tumours (Patard et al, 1995). An HLA-Cw7 restricted
antigen, encoded by the MAGE-A12 gene, was identified using a
bladder carcinoma line and an autologous CTL clone specific for
the tumour (Heidecker et al, 2000). Another bladder carcinoma
antigen was identified by autologous CTL, restricted to HLA-
B4403. The antigen is originated from a point mutation in a
ubiquitously expressed protein designated KIAA0205. The point
mutation was not identified in more than 100 tumours of various
histologic types (Gueguen et al, 1998).
The HHD system was developed in order to screen for HLA-A2.1
restricted antigens in a stable and reproducible murine system.
HHD mice, a combination of classical HLA transgenesis and
selective destruction of murine H-2, are D
b b2-microglobulin
(b2M) null mice, transgenic for a modified HLA-A2.1-b2-micro-
globulin single chain (Pascolo et al, 1997). It was demonstrated
that HHD mice selected the same immunodominant CTL epitopes
recognised by PBL in influenza-infected HLA-A2.1 individuals,
and, unlike traditional HLA transgenic mice, there is no murine
background response (Pascolo et al, 1997). Hence, these mice are a
useful tool for the identification and characterisation of potential
tumour-derived, HLA-A2.1 restricted, CTL epitopes. HLA-A2.1 is
the most widespread allele of HLA in the human population,
therefore our allele of choice for the search of tumour CTL
epitopes. The HHD system enabled the identification of TAA of
breast carcinoma (Carmon et al, 2000, 2002), and colon carcinoma
(Tirosh et al, 2003). A MAGE-A1 epitope of HLA-A2.1 was recently
identified (Pascolo et al, 2001), as well as shared epitopes of MAGE
genes (Graff-Dubois et al, 2002).
The current study aims at identification of HLA-A2.1-restricted
CLT epitopes of human bladder carcinoma. A DNA-chip-based
differential display analysis was performed, to identify over-
expressed and uniquely expressed genes of TCC, as compared to
the normal bladder. The MAGE-A8 gene was overexpressed in the
tumour, and not expressed in the normal tissue. A high-expression
level of MAGE-A8 was also demonstrated in TCC samples. MAGE-
A8 CTL epitopes were defined in this study.
MATERIALS AND METHODS
Mice
The derivation of HLA-A2.1/D
b-b2 monochain, transgenic, H-
2D
b b2m double-knockout mice (HHD mice) has been described
by Pascolo et al (1997). Mice were bred in the Weizmann Institute
of Science (Rehovot, Israel) and maintained and treated according
to NIH guidelines.
Cells
The following human TCC lines were utilised in this study: RT4,
T24, J82, TCCSUP, UM-UC3, SW780, 5637, and 1196. T24 is HLA-
A2 negative, it was transfected with the HHD construct to give the
T24 HHD clone. The TCC lines were maintained in McCOY’s 5A
medium, containing 10% FCS, 1mM glutamine, combined
antibiotics, 1mM sodium pyruvate, and 1% nonessential amino
acids. T24-HHD transfectants were maintained in the same
medium, added with 500mgml
 1 of Geneticin (Life Technologies
Inc, Paisley, UK).
RMA-S is a TAP-2-deficient lymphoma clone of C57BL/6 origin.
The RMA-S/HHD clone is an HHD transfectant of RMA-S cells.
The RMA-S/HHD/B7.1 clone is an HHD transfectant expressing
the murine B7.1 co-stimulatory molecule. EL4-HHD is a murine
thymoma, transfected with the HHD construct. T2 is a TAP-2-
deficient lymphoblastoid line of HLA-A2.1 genotype.
RMA-S and T2 cells were maintained in RPMI-1640 containing
10% FCS and combined antibiotics. RMA-S/HHD/B7 and EL4-
HHD cells were maintained in the same medium, added with
500mgml
 1 of Geneticin (Life Technologies Inc, Paisley, UK).
DNA chip-based differential display
Tissue samples from 10 TCC tumours and 10 transitional cell
layers of normal bladder samples were collected during surgery
and immediately frozen in liquid nitrogen (Hasharon Hospital,
Petach Tikva, Israel). RNA was extracted from each sample
separately using EasyRNA kit (Beit Haemek, Israel) and checked
for its integrity by agarose gel analysis. In all, 5mg of each of the 10
TCC samples was pooled. The pooled 50mg of TCC and control
RNA was used for cDNA synthesis using Superscript reverse
transcriptase (Life Technologies) and 18-mer oligo-dT primers.
The cDNA derived from TCC or normal bladder material was
further labelled with Cy3-dCTP or Cy5-dCTP (Amersham, UK),
respectively. The labelled cDNA was used for hybridisation to the
UniGEM 1 DNA chip, which contained approximately 10000
human cDNA clones (IncyteGenomics, Palo Alto, CA, USA).
Hybridisation, washing, and scanning of the slides were carried out
as previously described (Schena et al, 1996).
Data from GEM experiments were analysed by using the
GEMTools software package (Incyte). cDNA clones displaying
differential values were sequenced and their identity was defined.
MAGE-A8 expression by RT–PCR
TCC lines were grown in the tissue culture, and the cells were
harvested for RNA isolation. Tumour samples were collected in the
Carmel Medical Center (Haifa, Israel) by transurothral resection of
the bladder tumour (TURBT), and immediately frozen in liquid
nitrogen. Isolation of total RNA was performed by TRIREAGENT
(Molecular Research Center, Cincinnati, OH, USA) according to
the manufacturer’s instructions. Reverse transcription was per-
formed on 5mg of total RNA using an oligo (dT) 18-mer as a
primer. The cDNA quality was assured by expression of GAPDH, a
widely expressed metabolic gene. cDNA corresponding to 500ng of
total RNA was subjected to PCR amplification for 40 cycles, as
follows: 1min at 921C; 1min at 621C for MAGE-A, 8 or 561C for
GAPDH; 1min at 721C. Amplification was followed by a 10min
incubation at 721C. The following primers were employed: MAGE-
A8 sense primer – 50 ccc cag aga agc act gaa gaa g 30; MAGE-A8
anti sense primer – 50 ggt gag ctg ggt ccg gg 30; GAPDH sense
primer – 50 ACC ACA GTC CAT GCC ATC AC 30; GAPDH anti-
sense primer – 50 TCC ACC ACC CTG TTG CTG TA 30. Products of
the reaction were subjected to electrophoresis on 1.5% agarose gels
and monitored under UV light.
Peptide synthesis
Peptides were synthesised on an ABIMED AMS 422 multiple
peptide synthesiser (Abimed, Langenfeld, Germany), employing
the a-N-fluorenylmethoxy-cartonyl (Fmoc) strategy following the
commercially available manufacturer’s protocols. Peptide-chain
assembly was conducted on a 2-chlorotrityl-chloride resin
(Novabiochem, Laufelfingen, Switzerland). Crude peptides were
purified to homogeneity by reversed-phase HPLC on a semipre-
parative silica C-8 column (250 32 10mm
3; Lichnonorb RP-8;
Merck, Darmstadt, Germany). Elution was accomplished by a
linear gradient established between 0.1% TFA in water and 0.1%
TFA in 70% acetonitrile in water (vv
 1). Composition of the
products was determined by amino-acid analysis (automatic
amino-acid analyzer; Dionex, Sunnyvale, CA, USA) after extraction
acid hydrolysis. Molecular weight was ascertained by mass
spectrometry (VG Tofspec; Laser Desorption Mass Spectrometry;
Fisons, Manchester, UK). The MAGE-A8-encoded peptide
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ssequences are presented in Table 3. Other peptides that served in
this study are HLA-A2.1-binding peptides of HIV (TLNAWVKVV)
and Tyrosinase (YMNGTMSQV).
Peptide-binding assay and FACS staining
Peptide binding to MHC molecules was monitored by stabilisation
assays, in which TAP-deficient, HHD-transfected RMA-S cells
(RMA-S/HHD) are loaded with a peptide, and HHD expression on
the cell surface is monitored by FACS. In more detail, RMA-S/
HHD cells were washed with PBS and cultured overnight in serum-
free optiMEM medium (Life Technologies, Paisley, UK), at 26
OC,
in order to increase the surface expression of the HHD molecule.
In all, 1, 10, and 100mM of each peptide were added to 5 10
5
RMA-S/HHD cells in 100ml volume of opti-MEM for 3h at 261C,
and cultures were shifted to 371C for 2h, to decrease the
background level expression of peptide-free HHD molecules. The
cells were then stained with the HLA-specific W6/32mAb (Serotek,
UK) and monitored by FACS (Becton Dickinson, Canberra,
Australia).
Vaccination
HHD mice were immunised i.p., three times at 7-day intervals,
with 2 10
6 irradiated (5000rad), peptide-loaded RMA-S/HHD/
B7.1 transfectants. Alternatively, mice were immunised with 100mg
of peptide in 100ml of Incomplete Freund’s Adjuvant (IFA)
(DIFCO, Detroit, MI, USA) injected twice to the tail-base, in 14
days interval. For immunisation with cholera toxin (CT), 1mgo f
CT (List Biological Laboratories, Inc, Campbell, CA, USA) was
mixed with 12.5mg of the immunising peptide, in a volume of 16ml,
and dropped into the nozzle of anaesthetised mice. Immunisation
with CT was carried out three times, in 7-days intervals.
For all the vaccination modes, spleens were removed on day 10
after the last immunisation, and splenocytes were re-stimulated in
vitro, with one-third of the cells pre-pulsed with 100mM synthetic
peptides in optiMEM (Life Technologies, Paisley, UK) for 2h
at 371C, 5% CO2. Re-stimulated lymphocytes were cultured in
Table 1 The 20 most amplified genes of the TCC samples, as compared to normal bladder samples
Gene Accession number Fold of amplification
Homo sapiens keratin 6 isoform K6d (KRT6D) gene AA036948 53.3
ESTs W74581 52.3
ESTs R36967 38.9
Human nonspecific crossreacting antigen mRNA AA054073 36.5
KERATIN AA026418 23.9
GLYPICAN PRECURSOR W725759 23.2
ESTs {347362} W81087 14.1
INTERLEUKIN-8 PRECURSOR Y00787 13.4
ESTs H93048 11.6
KERATIN AA031736 11.3
C-PROTEIN N66106 10.9
ESTs W77796 10.5
KERATIN AA026642 10.4
MUCIN 1 PRECURSOR N27731 9.1
CORNIFIN B W72751 9
PLASMINOGEN ACTIVATOR INHIBITOR-2 AA032091 8.3
Human MAGE-8 antigen (MAGE8) gene U10693 7.8
ESTs H81053 7.6
CYSTATIN A AA022874 7.5
OSTEOPONTIN PRECURSOR AA021512 7.5
For technical details, see Materials and methods section.
Figure 1 MAGE-A8-gene expression in fresh tissue samples. Fresh TCC
samples (T1–T6), normal bladder (NB), and normal ureter (NU) were
collected and immediately frozen in liquid nitrogen. RNA was isolated,
cDNA was reverse-transcribed and served as a template for PCR
amplification with MAGE-A8-specific primers. GAPDH-specific primers
served to assure the cDNA quality. A DNA-free sample served as a
negative control for the reaction.
Table 2 MAGE-A8 gene expression in TCC lines
Cell line Tumour grade MAGE 8 expression
T24 III +
UM-UC3 Unknown +
RT4 I – papillary  
J82 III  
TCCSUP IV – metastases  
5637 II +
1196 IV  
SW780 I +
RNA was extracted from eight TCC lines, cDNA was reverse transcribed and served
as a template for PCR amplification with MAGE-A8 specific primers. In all the
examined samples, the cDNA quality was assured by GAPDH expression.
Table 3 MAGE-A8 peptides
Peptide Position Sequence
8.1 24–32 GLMDVQIPT
8.2 111–119 ALDEKVAEL
8.3 115–123 KVAELVRFL
8.4 45–53 LIMGTLEEV
8.5 179–187 YILVTCLGL
8.6 161–169 MQVIFGIDV
The position along the protein sequence and single-letter amino-acid sequence are
presented.
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sFigure 2 MAGE-A8-encoded peptide binding to HLA-A2.1. Peptides were loaded on the TAP-2-defficient, RMA-S HHD cells, at three different
concentrations, for 3h at 261C, and shifted for two more hours to 371C (see Materials and methods). Cells were then washed, stained with the BB7.2
monoclonal antibody (specific for HLA-A2) or with the corresponding isotype control (not shown), and monitored by FACS. The tyrosinase-encoded
peptide, a high binder of HLA-A2.1, served as a positive control, and a background level of peptide-free cells is demonstrated. Representative experiment
out of three.
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sRPMI-HEPES medium containing 10% FCS, 2mM glutamine, com-
bined antibiotics, 1mM sodium pyruvate, 25mM HEPES, 5 10
 5 M
bME, and 1% NEAA for 5 days. Viable cells (effectors) were
separated by Lympholyte-M (Cedarlane, Hornby, Canada) gradi-
ents, re-suspended, and admixed at different ratios with 5000
35S-methionine-labelled target cells. When served as target cells,
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for 3h. Cytolytic assays were carried out as described previously
(Carmon et al, 2000), in four effector-to-target concentrations, from
100:1 to 12.5:1. In all the experiments, the spontaneous release was
o25% of maximal release. Error was o5% of the mean of the
triplicates. Percent of specific lysis was calculated as follows: %
lysis¼(c.p.m. in experimental well c.p.m. spontaneous release)/
(c.p.m. maximal release c.p.m. spontaneous release) 100.
In vitro priming of human CTL
Leukapheresis products of two healthy donors were obtained from
Barzilai Medical Center (Ashkelon, Israel) according to the
Declaration of Helsinki Principles. Peripheral blood mononuclear
cells (PBMC) were isolated by centrifugation on Ficoll-Plaque Plus
gradients (Amersham, Sweden). The procedure was carried out
according to Thurner et al (1999), with minor modifications.
Briefly, in vitro priming was performed over autologous dendritic
cells (DC) that were prepared from monocytes by IL-4 and GM-
CSF treatment and matured with an IL-1b, IL-6, TNF-a, and PGE2
cocktail. Dendritic cells were pulsed with synthetic peptides and
PBMC were supplemented with IL-7. After 2 days, IL-2 was added
and renewed every 3 days. Second and third stimulations were
carried out on days 7 and 14 on peptide-pulsed, irradiated
monocytes. A fourth stimulation was carried out with autologous
DC, as above. At 7 days after the fourth stimulation, lymphocytes
were harvested and cytolytic assays were performed. In all the
experiments, the spontaneous release was o25% of maximal
release. The error was o5% of the mean of the triplicates. The
percentage of specific lysis was calculated as above.
RESULTS
We performed a cDNA chip-based differential display analysis, in
order to identify overexpressed genes of bladder carcinoma, as
compared to normal bladder mucosa. A pool of 10 normal and 10
tumour samples was hybridised to a cDNA chip containing 10000
cDNA sequences. The cDNA fragments are of 500–5000 bases,
originating from EST clones, and 40% are identified as known
genes. Hybridisation sensitivity is up to one part in 100000, which
is sufficient to detect single copy expressed genes. Two-fold
changes of expression of any gene on the microarray are
detectable.
About 480 genes, out of 10000 of the DNA chip, were found to
be induced two-fold or more in the TCC tissue, compared to
normal bladder tissue. Among the overexpressed genes of the
tumour is the gene for the MAGE-A8, which was amplified by 7.8-
fold, with background level of expression in the normal tissue
(Table 1). Since many MAGE family genes encode for TAA, we
chose to further examine the MAGE-A8 as a TAA.
To assess and validate the MAGE-A8 gene expression in TCC, we
examined its expression in fresh tumour samples and TCC lines by
RT–PCR. We examined 23 tumour samples, all collected by
transurothral resection of the bladder tumour (TURBT), and
immediately frozen in liquid nitrogen. RNA was isolated, and
reverse transcribed into cDNA. The cDNA quality of all the
examined samples was assured by GAPDH expression. Of the 23
examined samples, 17 were found to express the MAGE-A8 gene
(74%) and no expression was detected in normal bladder and
normal ureter samples (Figure 1). The PCR primers are designed
to bind to the second and third exons in the MAGE-A8 gene, to
avoid false-positive results due to genomic DNA contamination.
We also examined the MAGE-A8 gene expression in human TCC
lines (Table 2). Out of eight examined, four were found to express
the MAGE-A8 gene, among them the T24 cell line.
The MAGE-A8 protein sequence was screened for HLA-A2.1-
binding motifs. This analysis was performed through a world-wide
web interface (http://www-bimas.dcrt.nih.gov/molbio/hla_bind/in-
dex.html). This software scores every possible peptide along the
sequence for MHC binding. Every amino acid in the evaluated
peptide is scored according to its relative contribution to the
binding (Parker et al, 1994). We synthesised six peptides that were
predicted the highest for HLA-A2.1 binding, for further study
(Table 3). To confirm the MAGE-A8 peptides binding to HLA-
A2.1, we examined their potential to stabilise empty HLA
molecules. TAP-2-deficient, HHD-transfected, RMA-S cells
(RMA-S/HHD) were loaded with individual peptides at three
different concentrations (100, 10, and 1mM), and surface expres-
sion of HLA-A2.1 molecules was monitored by FACS (Figure 2).
All the six MAGE-A8 peptides were strong binders of HLA-A2.1.
Screening for the immunogenicity of HLA-A2.1-binding pep-
tides was carried out in HHD mice, which are eliminated for the
murine class I MHC, and transgenic for HLA-A2.1/D
b-b2-
microglobulin single chain (see Materials and methods, and
Pascolo et al, 1997). The a3 region of the HHD molecule is of
murine origin, to enable efficient interaction with CD8 molecules.
The MAGE-A8 peptide immunogenicity was examined in three
modes of vaccination. HHD mice were immunised with individual
peptides, splenocytes were re-stimulated in vitro with the
immunising peptide, and cytotoxicity against cells loaded with
the immunising peptide was measured. Immunisation with CT was
carried out intranasally. Peptide 8.1 is immunogenic, and peptides
8.2, 8.3, 8.4, and 8.5 are of low immunogenicity, and no
immunogenicity was detected for peptide 8.6 (Figure 3A). The
second mode of administration was with individual peptides in
IFA, injected to the base of the tail (Figure 3B). Peptides 8.1, 8.2,
8.3, and 8.4 showed higher lysis of peptide-loaded RMA-S/HHD
cells, than of unloaded RMA-S/HHD or RMA-S/HHD loaded with
an irrelevant HLA A2-binding peptide derived from HIV (not
shown). CTL induced by peptides 8.5 or 8.6 do not show any
specific lysis. The third mode of immunisation was with irradiated
RMS-S/HHD/B7 cells, loaded with individual peptides and injected
into the peritoneal cavity (Figure 3C). The highest immunogenicity
was observed for peptide 8.3,while peptide 8.2 shows low specific
lysis. For vaccination with peptide-loaded RMA-S/HHD/B7 cells,
peptide-pulsed EL4-HHD served as target cells, to avoid cross-
reaction with RMA-S/HHD/B7 target cells.
In the light of these data, we decided to further analyse the
antigenicity of peptides 8.1 and 8.3.
Peptides 8.1 and 8.3 were found to be the most immunogenic in
more than one of three modes of vaccinations, that is, both
peptides can elicit an efficient immune response towards the same
peptide-pulsed target cells. However, the existence of these
Figure 3 Immunogenicity of the MAGE-A8 peptides determined by three modes of vaccination. (A) HHD mice were immunised intranasally, three times,
with 12.5mg of individual peptides, dissolved in PBS and supplemented with 1mg of CT. At 10 days following the third immunisation, splenocytes were re-
sensitised with the immunising peptide for 4 days, and cytotoxicity was determined as described in Materials and methods. (B) Immunisation of HHD mice
was performed with 100mg of individual peptides, in IFA, injected twice in 14 days interval into the base of the tail. Cytotoxicity was determined subsequent
to splenocyte re-sensitisation. (C) HHD mice were vaccinated three times, in 7 days intervals, with RMAS/HHD/B7 cells, loaded with individual peptides.
Splenocytes were re-sensitised with the immunising peptide and cytotoxicity was monitored using peptide-pulsed EL4-HHD as targets. Data are presented
as lytic units 30 (LU30), which are defined as the number of cells required for 30% target lysis (see Materials and methods for more details). Representative
experiment out of three.
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speptides as natural epitopes on tumour cells should be demon-
strated. Therefore, we immunised HHD mice with each of the
peptides loaded on RMA-S/HHD/B7 cells and the cytotoxic activity
against the T24-HHD cells was calculated. T24-HHD is a human
TCC line, expressing the MAGE-A8 gene (Table 3), which was
transfected with the HHD construct (data not shown). Both
peptides 8.1 and 8.3 elicited an HLA-A2.1-restricted specific
response to the T24-HHD cells (Figure 4), such a response was
not observed when HHD mice were immunised with the HIV-
derived unrelated peptide. These results show that both the 8.1 and
8.3 peptides are processed and presented on HLA molecules of the
T24-HHD tumour cells.
HHD mice can predict well peptide immunogenicity, yet
immunogenicity has to be examined also in humans. To examine
whether peptides 8.1 and 8.3 can prime CTL in human
lymphocytes in vitro, PBMC of healthy donors were collected by
leukapheresis, and kept as frozen aliquots. Lymphocytes were
stimulated in the presence of IL-2 and IL-7 four times. The first
and fourth stimulations were carried out with DC loaded with
peptide 8.1 or 8.3. The second and third stimulations were
accomplished by peptide-pulsed irradiated monocytes. At 7 days
following the fourth stimulation, cytotoxicity assays were per-
formed. For the donor IM, peptides 8.1 and 8.3 primed a specific
cytotoxic response at low E:T ratios (Figure 5A,B). For AR,
peptide 8.3, but not 8.1, primed a specific response (Figure 5C,D).
Therefore, the immunogenic potential of peptide 8.3 was demon-
strated in both donors, and that of peptide 8.1 in one donor.
Hence, there is no absolute ‘tolerance barrier’ that prevents
priming of human cytotoxic response towards the MAGE-A8
peptides.
DISCUSSION
This study is aimed at identification of TAA peptides of human
TCC. The first human TAAs were identified by genetic methods,
utilising T cells against autologous cancer cells (van der Bruggen
et al, 1991; Kawakami et al, 1994). Alternatively, TAA peptides
were identified by biochemical methods (Cox et al, 1994;
Mandelboim et al, 1994) or peptide libraries (Chen, 1999). Our
study is based on a different strategy, of ‘reverse immunology’.
Most methods depend on patient-derived T cells, which already
failed to react against the tumour. Reverse immunology aims to
identify candidate antigens, and to look for possible epitopes
within them.
To identify potential tumour antigens, gene expression profiles
of TCC vs normal bladder were examined by DNA microarray. The
analysis provided us a comprehensive source of information, and
enabled to identify expression of genes that were not known to
correlate with TCC.
Several parameters are required for a probable TAA gene. First,
a high expression level is required, in order to yield higher epitope
expression level on the cell surface (Yewdell, 2001). A second
requirement is for minimal expression level in the normal tissue,
to avoid autoimmune complication. For a higher clinical relevance,
TAA genes should be expressed in a high percentage of tumours,
preferentially of various types. The MAGE-A8 fits these require-
ments, it was amplified by 7.8-fold, with no evidence of expression
in the normal tissue. RT–PCR analysis revealed high expression
level in fresh tumour samples (17 of 23), no expression in samples
of normal bladder and ureter (Figure 1), and four of eight TCC
lines (Table 2). As was previously described, 46% of hepatocellular
carcinomas (Tahara et al, 1999) and 44% of colorectal carcinomas
(Hasegawa et al, 1998) expressed the MAGE-A8 gene. Moreover,
expression of MAGE-A8 gene in adult tissue is limited to the male
germ line, which does not express HLA molecules, and to the
placenta (De Plaen et al, 1994).
Ideally, a TAA would be functionally related to the tumorigen-
esis and to metastases formation process. Since the role of MAGE-
A8 is not defined, its involvement in tumour formation and
progression is not clear. MAGE genes are expressed as a result of
DNA demethylation in tumour cells (Barker and Salehi, 2002).
Therefore, it is not clear whether MAGE genes expression is part of
the tumour formation process, or its byproduct. It was recently
shown that MAGE genes are expressed early in lung carcinogenesis
(Jang et al, 2001), and therefore may serve both for early detection
and for treatment of cancer cells. Clinical trials with MAGE
peptides are currently carried out, mainly for melanoma (Parmiani
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Figure 4 Antigenicity of peptides 8.1 and 8.3. HHD mice were vaccinated three times, in 7 days intervals, with RMA-S/HHD/B7 cells, loaded with
peptides 8.1, 8.3, or an HIV-encoded peptide. At 10 days following the third immunisation, spleens were removed and splenocytes were re-sensitised with
the immunising peptide, for 4 days. Cytotoxicity was determined against the T24 or T24-HHD cells, both expressing the MAGE-A8 gene. Data are
presented as lytic units 30 (LU30), which is defined as the number of cells required for 30% target lysis (see Materials and methods for more details).
Representative experiment out of three.
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set al, 2002). Melanoma regression following vaccination with
MAGE-3 peptide was demonstrated, with low-frequency CTL
response (Coulie et al, 2001). Another study (Nishiyama et al,
2001) describes the use of autologous DC pulsed with an HLA-A24-
restricted MAGE-A3-encoded peptide. In three of four patients,
significant reduction in the size of metastases was observed, and a
complete response was detected in one patient. This pilot study
reveals the potential use of TAA peptides for TCC immunotherapy.
We next looked for potential T-cell epitopes of MAGE-A8,
utilising the HHD system. It was shown that HHD mice selected
the same immunodominant CTL epitopes as recognised by PBL in
influenza-infected HLA-A2.1 individuals (Pascolo et al, 1997).
Unlike traditional HLA transgenic mice, HHD mice T-cell response
is HLA-A2.1 restricted, with no murine background. It was shown
that the TCR repertoire of HHD mice in response to HLA-A2.1-
restricted antigens is larger that that of traditional HLA-A2.1
transgenic mice (Firat et al, 2002). Thus, these mice are
presumably an ideal tool for the identification and characterisation
of potential tumour-derived HLA-A2.1-restricted CTL epitopes.
A potent TAA peptide epitope should be a good HLA binder,
immunogenic, and antigenic. To this end, we identified six HLA-
A2.1-binding peptides of MAGE-A8 (Table 3, Figure 2). The
immungenicity of peptide epitopes may vary between different
modes of vaccination (Firat et al, 1999). The immunogenic
potential of the MAGE-A8 peptides was examined in three
vaccination modes; peptides delivered intranasally with CT as a
mucosal adjuvant, peptides in complete Freund’s adjuvant (CFA)
injected to the tail base, and peptide loaded on RMA-S/HHD/B7
cells injected intraparitoneally (Figure 3A–C, respectively). All
these modes of vaccination were proven to give efficient
immunisation in mice (Porgador et al, 1997; Carmon et al, 2002;
Firat et al, 2002). Taking into account that peptides 8.1 and 8.3
were immunogenic in more than one mode of vaccination, we
decided to further investigate the potential of peptides 8.1 and 8.3
to serve as TAA epitopes.
The screening system enables us to identify immunogenic
peptides, but antigenicity is not addressed. The potential of
synthetic peptide to induce an immune response does not tell
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Figure 5 In vitro priming of a CTL response in human lymphocytes towards peptides 8.1 and 8.3. Peripheral blood mononuclear cells were collected by
leukapheresis from two healthy male donors, designated IM (A, B) and AR (C, D). Lymphocytes were primed with peptide-pulsed autologous DC.
Peripheral blood mononuclear cells were supplemented with IL-7, and, 2 days later, IL-2 was added and renewed every 3 days. The next two stimulations
were carried out every 7 days over peptide-pulsed monocytes, and a fourth stimulation was carried out with peptide-pulsed autologous DC. At 7 days
following the last stimulation, cytotoxicity was determined against peptide-pulsed or nonpulsed T2 cells as targets.
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sabout its existence as a natural epitope. To this end, we examined
whether T cells specific for each of the peptides can specifically
lyse the T24-HHD cells, as compared to T24 cells (Figure 4). T24
cells express the MAGE-A8 gene (Table 2), and so do T24-HHD
cells (not shown). Both peptides 8.1 and 8.3, but not the irrelevant
HIV peptide, induced a cytotoxic response against the T24-HHD
cells. The cytotoxic response is HLA-A2.1 restricted, since lysis of
T24 cells was at a low level. Thus, both peptides 8.1 and 8.3 are
presented by HLA-A2.1 molecules on the surface of MAGE-A8-
expressing cells.
The immunogenic potential of the 8.1 and 8.3 peptides was
demonstrated in HHD mice. Since tolerance to immune-dominant
peptides from self proteins was demonstrated (Theobald et al,
1997; Colella et al, 2000), we tested whether these peptides can
prime CTL in humans. For peptide 8.1, immunogenicity was
shown in one of two healthy donors, and for peptide 8.3 in both
donors (Figure 5A–D). The killing activity was limited, as
compared to the background level of nonpulsed cells, but lack of
activation was detected for peptide 8.1 with AR donor only.
Moreover, in the case of IM, cytotoxicity was observed in a
relatively low effector-to-target ratio. We therefore conclude that
both peptides are capable of priming cytotoxic activity in human
lymphocytes. CD8
þ cells in HHD mice are selected on a single
allele of HLA-A2.1. Therefore, negative selection is limited, and the
TCR repertoire is wider than in human (Firat et al, 2002). TCR
selection in human is carried out through up to six HLA alleles for
class I HLA, and that could limit the TCR repertoire. Even though,
priming of cytotoxic cells is within reach.
The search for TCC-associated antigens is limited. There
are only few cases in which TCC-specific TAA epitopes
were identified (Gueguen et al, 1998; Heidecker et al, 2000),
in spite of the immunogenic potential of this tumour, since
TCC is among few types of cancers that are immunotherapy
responsive. Intravesical delivery of BCG is a standard therapy
for superficial bladder cancer, and has positive outcomes
on tumour recurrence rate, disease progression, and prolongation
of survival (Nseyo and Lamm, 1997). A positive clinical
outcome was observed by other modalities of immunotherapy,
such as the use of a-interferon (aIFN) and keyhole
limpet hemocyanin (KLH). The use of TAA peptides is advanta-
geous, since it can target the tumour cells specifically, with
lower side effects than nonspecific immunotherapy. A combined
therapy of local immune stimulation with the use of specific
tumour antigens could be of great clinical value. The MAGE-A8
peptides, as well as other TAA peptides, could serve for such a
therapy.
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